Acadia Healthcare Co Inc (NASDAQ:ACHC) released its first-quarter results for 2026 after the market close on Wednesday, delivering a mixed bag that has left investors selling off shares in after-hours trading. While the company managed to beat bottom-line expectations, a slight revenue miss and a cautious near-term outlook regarding supplemental payments are weighing on sentiment, sending the stock down more than 5.6% after the bell.
Revenue and EPS: A Tale of Two Metrics
For the quarter ended March 31, 2026, Acadia reported revenue of $828.8 million, an increase of 7.6% year-over-year. This figure came in just below the analyst consensus estimate of approximately $839.4 million, representing a miss of roughly 1.3%. On the earnings front, however, the company outperformed. Adjusted net income attributable to Acadia was $33.3 million, or $0.37 per diluted share, which handily beat the analyst estimate of $0.27 per share.
- Reported Revenue: $828.8 million (Estimate: $839.4 million)
- Adjusted EPS: $0.37 (Estimate: $0.27)
- Revenue Growth: +7.6% year-over-year
- Adjusted EBITDA: $144.2 million (up from $134.2 million)
The headline beat on earnings was driven by strong volume growth in the Acute and Residential Treatment (RTC) segments, along with disciplined cost controls that helped push Adjusted EBITDA above the high end of the company’s own guidance range.
Key Drivers: Acute Strength Offsets Specialty Weakness
Acadia’s performance in the quarter was largely a story of its core Acute inpatient business. Acute Inpatient Psychiatric Facility revenue surged 14% year-over-year to $470.7 million, fueled by a 6.2% increase in volumes. Management attributed this to expanded capacity from both newly constructed and existing facilities.
In contrast, the Specialty Treatment segment saw a 7% revenue decline to $128.1 million. The company cited ongoing challenges related to specific facilities in Pennsylvania and the impact of closures that occurred after the first quarter of 2025.
Other segments showed more modest gains:
- Comprehensive Treatment Facilities (CTC): Revenue of $140.4 million, up 2.5%.
- Residential Treatment Facilities (RTC): Revenue of $89.6 million, up 6.3%.
Outlook: A Narrowed Path but Near-Term Headwinds
Acadia provided a rare second-quarter guidance update, citing the material impact of out-of-period supplemental payments received from the state of Tennessee in Q2 of 2025. For the second quarter of 2026, the company expects:
- Revenue: $835 million to $850 million (Estimate: $883.6 million)
- Adjusted EBITDA: $142 million to $152 million
- Adjusted EPS: $0.30 to $0.40
The Q2 revenue guidance range falls notably short of the analyst consensus of $883.6 million, which appears to be a primary catalyst for the negative market reaction. Acadia explicitly noted that its Q2 guidance assumes no incremental new supplemental payments, a conservative stance that likely disappointed investors expecting a more robust top-line trajectory.
For the full year 2026, Acadia raised the low end of its guidance ranges:
- Revenue: $3.37 billion to $3.45 billion (Estimate: $3.48 billion)
- Adjusted EBITDA: $580 million to $615 million (up from $575M - $610M)
- Adjusted EPS: $1.35 to $1.60 (up from $1.30 - $1.55)
- Operating Cash Flow: $285 million to $325 million (up from $280M - $320M)
While the full-year guidance was tweaked higher, the midpoint of the revenue forecast still sits below consensus, suggesting the market had priced in a more aggressive ramp-up in the back half of the year.
Market Reaction
The after-market sell-off of over 5.6% suggests investors are focusing on the revenue miss and the soft Q2 outlook rather than the strong earnings beat. The substantial gap between the Q2 guidance midpoint ($842.5 million) and the analyst estimate ($883.6 million) is a stark discrepancy that will likely put pressure on the stock in the coming session. Additionally, the company expects its net leverage to tick up to 4.4x-4.5x by the end of Q2 due to the base effect of the prior year’s supplemental payments, which could raise concerns about balance sheet flexibility.
The Bottom Line
Acadia’s operational execution, particularly in its core acute business, is solid. The company is adding beds, controlling costs, and generating strong cash flow. However, the market is clearly punishing the stock for the revenue miss and, more critically, the cautious near-term revenue outlook. The absence of anticipated supplemental payments in the company’s own forecast creates a near-term cloud that overshadows the earnings beat.
For a deeper dive into Acadia’s historical earnings performance and to view future projections and analyst estimates, visit the ACHC earnings page and the analyst ratings page.
This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.